Fundraising Fox

FluGen

Madison, US · Wisconsin corporation · 3 known investors

Biotech

Founders & leadership

PV
Paul V. RadspinnerFounder
PB
Pamuk BilselExecutive
DM
Deven McGlennNamed on SEC filing
SL
Scott L. KlugNamed on SEC filing
RR
Russell R. SmestadNamed on SEC filing
BR
Bryan RenkNamed on SEC filing

Board

PM
Phillip M. HalpernBoard director
TF
Terence F. KellyBoard director
DS
Dan StinchcombBoard director
CB
C. Boyd ClarkeBoard director
DG
David G. WalshBoard director
PW
Paul WeissBoard director

Investors · 3

Venture ManagementMadison
Wisconsin Investment PartnersMadison · $5K – $100K
Clarevia VenturesreportedMadison · $250K – $2.5M

Reported raises · per SEC filings

Form D private placements

$33.9M disclosed across 5 rounds · 2014–2020

▶$8.2MraisedMay 2020 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul WeissDirector
  • Eric PatzerDirector
  • David G. WalshDirector
  • Paul V. RadspinnerExecutive Officer, Director
  • Erik IversonDirector
  • C. Boyd ClarkeDirector
  • David NewbergDirector
  • Pamuk BilselExecutive Officer
Offering amount
$8.5M
Amount sold
$8.2M
First sale
Apr 2020
Incorporated
Corporation, Wisconsin
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.6MraisedNov 2018 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pamuk BilselExecutive Officer
  • C. Boyd ClarkeDirector
  • Michael WagnerDirector
  • Paul WeissDirector
  • Phillip M. HalpernDirector
  • Paul V. RadspinnerExecutive Officer, Director
  • David G. WalshDirector
Offering amount
$5.6M
Amount sold
$5.6M
First sale
Oct 2018
Incorporated
Corporation, Wisconsin
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedAug 2017 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael WagnerDirector
  • David G. WalshDirector
  • Phillip M. HalpernDirector
  • Paul V. RadspinnerExecutive Officer, Director
  • Dan StinchcombDirector
  • Pamuk BilselExecutive Officer
  • Paul WeissDirector
  • C. Boyd ClarkeDirector
Offering amount
$5.5M
Amount sold
$5.5M
First sale
Jun 2017
Incorporated
Corporation, Wisconsin
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.4MraisedApr 2017 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dan StinchcombDirector
  • C. Boyd ClarkeDirector
  • Phillip M. HalpernDirector
  • Paul V. RadspinnerExecutive Officer, Director
  • David G. WalshDirector
  • Pamuk BilselExecutive Officer
  • Paul WeissDirector
  • Craig HeimDirector
Offering amount
$11.4M
Amount sold
$11.4M
First sale
Aug 2015
Incorporated
Corporation, Wisconsin
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMay 2014 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pamuk BilselExecutive Officer
  • Deven McGlennDirector
  • Terence F. KellyDirector
  • Scott L. KlugDirector
  • David G. WalshDirector
  • Russell R. SmestadDirector
  • Bryan RenkDirector
  • Phillip M. HalpernDirector
  • Paul V. RadspinnerExecutive Officer, Director, Promoter
Offering amount
$3.9M
Amount sold
$3.2M
First sale
Feb 2014
Incorporated
Corporation, Wisconsin
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
BiPar Sciences21 shared keywordsBiopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.

Companies competing with FluGen for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$349.6K
National Institutes of Health (NIH)National Institutes of HealthPhase II2018$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2017$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2015$225K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2014$600K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$220.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine - BioSpacebiospace.com · Jul 2021Madison pharmaceutical developer FluGen raises $5.6 millionbiztimes.com · Nov 2018Flugen, Inc. Raises $2M More, Provides Update on Phase I Trial - BioSpacebiospace.com · Apr 2017FluGen Completes $12M Series A Financing - FinSMEsfinsmes.com · Aug 2015WI-based FluGen raises $3.4M for universal flu vaccine phase I trial - University Research Park | Madison, WIuniversityresearchpark.org · Jun 2014FluGen raises $12 million in new investments for flu vaccinesjsonline.com

Frequently asked questions

Who founded FluGen?
FluGen was founded by Paul V. Radspinner.
Who are FluGen's investors?
FluGen's investors include Venture Management, Wisconsin Investment Partners, Clarevia Ventures.
How much funding has FluGen raised?
FluGen has disclosed $33.9M raised across 5 rounds.
Where is FluGen headquartered?
FluGen is headquartered in Madison, US.